Eintrag weiter verarbeiten
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients
Gespeichert in:
| Zeitschriftentitel: | Clinical Pharmacology in Drug Development |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Clinical Pharmacology in Drug Development, 3, 2014, 1, S. 34-42 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Chen, Xuejun Shi, Jack G. Emm, Thomas Scherle, Peggy A. McGee, Ryan F. Lo, Yvonne Landman, Robert R. Punwani, Naresh G. Williams, William V. Yeleswaram, Swamy Chen, Xuejun Shi, Jack G. Emm, Thomas Scherle, Peggy A. McGee, Ryan F. Lo, Yvonne Landman, Robert R. Punwani, Naresh G. Williams, William V. Yeleswaram, Swamy |
|---|---|
| author |
Chen, Xuejun Shi, Jack G. Emm, Thomas Scherle, Peggy A. McGee, Ryan F. Lo, Yvonne Landman, Robert R. Punwani, Naresh G. Williams, William V. Yeleswaram, Swamy |
| spellingShingle |
Chen, Xuejun Shi, Jack G. Emm, Thomas Scherle, Peggy A. McGee, Ryan F. Lo, Yvonne Landman, Robert R. Punwani, Naresh G. Williams, William V. Yeleswaram, Swamy Clinical Pharmacology in Drug Development Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients Pharmacology (medical) Pharmaceutical Science |
| author_sort |
chen, xuejun |
| spelling |
Chen, Xuejun Shi, Jack G. Emm, Thomas Scherle, Peggy A. McGee, Ryan F. Lo, Yvonne Landman, Robert R. Punwani, Naresh G. Williams, William V. Yeleswaram, Swamy 2160-763X 2160-7648 Wiley Pharmacology (medical) Pharmaceutical Science http://dx.doi.org/10.1002/cpdd.77 <jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single‐dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%, and 65%, respectively, in subjects with mild, moderate, and severe hepatic impairment compared to healthy subjects with no correlation between exposure of ruxolitinib and the degree of hepatic impairment. The pharmacodynamics (PD) data were consistent with ruxolitinib pharmacokinetics (PK). The renal impairment study showed a surprising finding. While there was no change in ruxolitinib PK with varying degrees of renal impairment, the PD showed increasing pharmacological activity with increased severity of renal impairment. Analysis of the metabolite exposures revealed that active metabolites contributed to the observed incremental increase in PD activity. The recovery of ruxolitinib in dialysate was negligible. The starting dose of ruxolitinib in subjects with any hepatic impairment or moderate or severe renal impairment should be decreased to 10 mg twice daily (BID) if their platelet counts are between 100 × 10<jats:sup>9</jats:sup>/L and 150 × 10<jats:sup>9</jats:sup>/L. Subjects on dialysis should initiate dosing with a single dose of 15 or 20 mg, based on platelet counts, with dosing only on the days of dialysis.</jats:p></jats:sec> Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients Clinical Pharmacology in Drug Development |
| doi_str_mv |
10.1002/cpdd.77 |
| facet_avail |
Online |
| finc_class_facet |
Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jcGRkLjc3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jcGRkLjc3 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2014 |
| imprint_str_mv |
Wiley, 2014 |
| issn |
2160-763X 2160-7648 |
| issn_str_mv |
2160-763X 2160-7648 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
chen2014pharmacokineticsandpharmacodynamicsoforallyadministeredruxolitinibincb018424phosphateinrenalandhepaticimpairmentpatients |
| publishDateSort |
2014 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Pharmacology in Drug Development |
| source_id |
49 |
| title |
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_unstemmed |
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_full |
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_fullStr |
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_full_unstemmed |
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_short |
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_sort |
pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (incb018424 phosphate) in renal and hepatic impairment patients |
| topic |
Pharmacology (medical) Pharmaceutical Science |
| url |
http://dx.doi.org/10.1002/cpdd.77 |
| publishDate |
2014 |
| physical |
34-42 |
| description |
<jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single‐dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%, and 65%, respectively, in subjects with mild, moderate, and severe hepatic impairment compared to healthy subjects with no correlation between exposure of ruxolitinib and the degree of hepatic impairment. The pharmacodynamics (PD) data were consistent with ruxolitinib pharmacokinetics (PK). The renal impairment study showed a surprising finding. While there was no change in ruxolitinib PK with varying degrees of renal impairment, the PD showed increasing pharmacological activity with increased severity of renal impairment. Analysis of the metabolite exposures revealed that active metabolites contributed to the observed incremental increase in PD activity. The recovery of ruxolitinib in dialysate was negligible. The starting dose of ruxolitinib in subjects with any hepatic impairment or moderate or severe renal impairment should be decreased to 10 mg twice daily (BID) if their platelet counts are between 100 × 10<jats:sup>9</jats:sup>/L and 150 × 10<jats:sup>9</jats:sup>/L. Subjects on dialysis should initiate dosing with a single dose of 15 or 20 mg, based on platelet counts, with dosing only on the days of dialysis.</jats:p></jats:sec> |
| container_issue |
1 |
| container_start_page |
34 |
| container_title |
Clinical Pharmacology in Drug Development |
| container_volume |
3 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339831290855429 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:54:07.602Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Pharmacokinetics+and+pharmacodynamics+of+orally+administered+ruxolitinib+%28INCB018424+phosphate%29+in+renal+and+hepatic+impairment+patients&rft.date=2014-01-01&genre=article&issn=2160-7648&volume=3&issue=1&spage=34&epage=42&pages=34-42&jtitle=Clinical+Pharmacology+in+Drug+Development&atitle=Pharmacokinetics+and+pharmacodynamics+of+orally+administered+ruxolitinib+%28INCB018424+phosphate%29+in+renal+and+hepatic+impairment+patients&aulast=Yeleswaram&aufirst=Swamy&rft_id=info%3Adoi%2F10.1002%2Fcpdd.77&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339831290855429 |
| author | Chen, Xuejun, Shi, Jack G., Emm, Thomas, Scherle, Peggy A., McGee, Ryan F., Lo, Yvonne, Landman, Robert R., Punwani, Naresh G., Williams, William V., Yeleswaram, Swamy |
| author_facet | Chen, Xuejun, Shi, Jack G., Emm, Thomas, Scherle, Peggy A., McGee, Ryan F., Lo, Yvonne, Landman, Robert R., Punwani, Naresh G., Williams, William V., Yeleswaram, Swamy, Chen, Xuejun, Shi, Jack G., Emm, Thomas, Scherle, Peggy A., McGee, Ryan F., Lo, Yvonne, Landman, Robert R., Punwani, Naresh G., Williams, William V., Yeleswaram, Swamy |
| author_sort | chen, xuejun |
| container_issue | 1 |
| container_start_page | 34 |
| container_title | Clinical Pharmacology in Drug Development |
| container_volume | 3 |
| description | <jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single‐dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%, and 65%, respectively, in subjects with mild, moderate, and severe hepatic impairment compared to healthy subjects with no correlation between exposure of ruxolitinib and the degree of hepatic impairment. The pharmacodynamics (PD) data were consistent with ruxolitinib pharmacokinetics (PK). The renal impairment study showed a surprising finding. While there was no change in ruxolitinib PK with varying degrees of renal impairment, the PD showed increasing pharmacological activity with increased severity of renal impairment. Analysis of the metabolite exposures revealed that active metabolites contributed to the observed incremental increase in PD activity. The recovery of ruxolitinib in dialysate was negligible. The starting dose of ruxolitinib in subjects with any hepatic impairment or moderate or severe renal impairment should be decreased to 10 mg twice daily (BID) if their platelet counts are between 100 × 10<jats:sup>9</jats:sup>/L and 150 × 10<jats:sup>9</jats:sup>/L. Subjects on dialysis should initiate dosing with a single dose of 15 or 20 mg, based on platelet counts, with dosing only on the days of dialysis.</jats:p></jats:sec> |
| doi_str_mv | 10.1002/cpdd.77 |
| facet_avail | Online |
| finc_class_facet | Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jcGRkLjc3 |
| imprint | Wiley, 2014 |
| imprint_str_mv | Wiley, 2014 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 2160-763X, 2160-7648 |
| issn_str_mv | 2160-763X, 2160-7648 |
| language | English |
| last_indexed | 2024-03-01T15:54:07.602Z |
| match_str | chen2014pharmacokineticsandpharmacodynamicsoforallyadministeredruxolitinibincb018424phosphateinrenalandhepaticimpairmentpatients |
| mega_collection | Wiley (CrossRef) |
| physical | 34-42 |
| publishDate | 2014 |
| publishDateSort | 2014 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Clinical Pharmacology in Drug Development |
| source_id | 49 |
| spelling | Chen, Xuejun Shi, Jack G. Emm, Thomas Scherle, Peggy A. McGee, Ryan F. Lo, Yvonne Landman, Robert R. Punwani, Naresh G. Williams, William V. Yeleswaram, Swamy 2160-763X 2160-7648 Wiley Pharmacology (medical) Pharmaceutical Science http://dx.doi.org/10.1002/cpdd.77 <jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single‐dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%, and 65%, respectively, in subjects with mild, moderate, and severe hepatic impairment compared to healthy subjects with no correlation between exposure of ruxolitinib and the degree of hepatic impairment. The pharmacodynamics (PD) data were consistent with ruxolitinib pharmacokinetics (PK). The renal impairment study showed a surprising finding. While there was no change in ruxolitinib PK with varying degrees of renal impairment, the PD showed increasing pharmacological activity with increased severity of renal impairment. Analysis of the metabolite exposures revealed that active metabolites contributed to the observed incremental increase in PD activity. The recovery of ruxolitinib in dialysate was negligible. The starting dose of ruxolitinib in subjects with any hepatic impairment or moderate or severe renal impairment should be decreased to 10 mg twice daily (BID) if their platelet counts are between 100 × 10<jats:sup>9</jats:sup>/L and 150 × 10<jats:sup>9</jats:sup>/L. Subjects on dialysis should initiate dosing with a single dose of 15 or 20 mg, based on platelet counts, with dosing only on the days of dialysis.</jats:p></jats:sec> Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients Clinical Pharmacology in Drug Development |
| spellingShingle | Chen, Xuejun, Shi, Jack G., Emm, Thomas, Scherle, Peggy A., McGee, Ryan F., Lo, Yvonne, Landman, Robert R., Punwani, Naresh G., Williams, William V., Yeleswaram, Swamy, Clinical Pharmacology in Drug Development, Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients, Pharmacology (medical), Pharmaceutical Science |
| title | Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_full | Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_fullStr | Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_full_unstemmed | Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_short | Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| title_sort | pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (incb018424 phosphate) in renal and hepatic impairment patients |
| title_unstemmed | Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients |
| topic | Pharmacology (medical), Pharmaceutical Science |
| url | http://dx.doi.org/10.1002/cpdd.77 |